SRC and ovarian carcinoma: [17–19] Employing genetically engineered mouse models (targeted disruption of Nedd9, Nedd9−/− genotype) in ovarian carcinoma, Gabbasov et al. showed that mice with the Nedd9−/− genotype exhibited decreased tumor growth and incidence of ascites via reduced expression and activation of signaling proteins, including SRC/STAT3 [19].